Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 328

Sort by

Sort Order Select

Journal Articles

Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab

Bridget Austin, Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Sheila Pierson, Larissa Borys, Kayla McHugh, Abiola Irvine, Kelley Dacus, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan Lim, Gordan Srkalovic, Frits van Rhee, Joshua Brandstadter, David Fajgenbaum

Blood (2025) 146 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2025-3009

Published: 2025

Journal Articles

Comparable response rates to therapies in idiopathic multicentric castleman disease patients with and without expert-confirmed diagnoses

Larissa Borys, Bridget Austin, Mary Jo Lechowicz, Sheila Pierson, Kayla McHugh, Abiola Irvine, Kelley Dacus, Adam Bagg, Daisy Alapat, Amy Chadburn, Megan Lim, Gordan Srkalovic, Frits van Rhee, Joshua Brandstadter, David Fajgenbaum

Blood (2025) 146 (Supplement 1): 6569.

https://doi.org/10.1182/blood-2025-6569

Published: 2025

Journal Articles

Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor

Kayla McHugh, Yuan Huang, Bridget Austin, Larissa Borys, Abiola Irvine, Daisy Alapat, Adam Bagg, Amy Chadburn, Mary Jo Lechowicz, Megan Lim, Gordan Srkalovic, Frits van Rhee, David Fajgenbaum, Lu Zhang, Joshua Brandstadter

Blood (2025) 146 (Supplement 1): 1228.

https://doi.org/10.1182/blood-2025-1228

Published: 2025

Journal Articles

Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors

Hira Cheema, Asis Shrestha, Syed Naqvi, Sanjay Muttineni, Sasya Dronavalli, Jawad Alrawabdeh, Marah Alzubi, Sharmilan Thanendrarajan, Maurizio Zangari, John D Shaughnessy, Jr, Fenghuang Zhan, Carolina Schinke, Frits van Rhee, Samer Al Hadidi

Blood (2025) 146 (Supplement 1): 4599.

https://doi.org/10.1182/blood-2025-4599

Published: 2025

Journal Articles

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, Raja Prince-Eladnani, Ajay Nooka, David Vesole, Barry Paul, Parameswaran Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin Van Vliet, David Siegel, Saad Usmani, Frits van Rhee

Blood (2025) 146 (Supplement 1): 2220.

https://doi.org/10.1182/blood-2025-2220

Published: 2025

Journal Articles

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network.

Syed Naqvi, Ejaz Shah, Firas Jafri, Manpreet Saini, Syed Abutalib, Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Samer Al Hadidi, Frits van Rhee

Blood (2025) 146 (Supplement 1): 7597.

https://doi.org/10.1182/blood-2025-7597

Published: 2025

Journal Articles

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network.

Syed Naqvi, Manpreet Saini, Ejaz Shah, Firas Jafri, Syed Abutalib, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee

Blood (2025) 146 (Supplement 1): 7595.

https://doi.org/10.1182/blood-2025-7595

Published: 2025

Journal Articles

Siltuximab-mediated suppression of CRP is associated with clinical response in idiopathic multicentric castleman disease

Jean-Francois Rossi, Azhaar Ashraf, Yildiz Kelahmetoglu, David Fajgenbaum, Saishravan Shyamsundar, Frits van Rhee

Blood (2025) 146 (Supplement 1): 4788.

https://doi.org/10.1182/blood-2025-4788

Published: 2025

Journal Articles

Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum

David E Mery, Samer Al Hadidi, Clyde Bailey, Eric Siegel, Hongwei Xu, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2025) 146 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2025-2172

Published: 2025

Journal Articles

Transcriptomic and pathological insights into PI3K–Akt pathway activation in idiopathic multicentric castleman disease, tafro and NOS subtypes

Tomoka Haratake, Midori Filiz Nishimura, Asami Nishikori, Yoshito Nishimura, Michael Gonzalez, Daisuke Ennishi, Manaka Tsunoda, David Fajgenbaum, Frits van Rhee, Shuji Momose, Yasuharu Sato

Blood (2025) 146 (Supplement 1): 4782.

https://doi.org/10.1182/blood-2025-4782

Published: 2025

Journal Articles

Real-world outcomes of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) following CAR T-cell therapy: A multicenter retrospective study from the trinetx global network

Syed Naqvi, Ejaz Shah, Firas Jafri, Syed Muhammad Ali Najafi, Manpreet Saini, Syed Abutalib, Maurizio Zangari, Frits van Rhee, Ankur Varma

Blood (2025) 146 (Supplement 1): 7247.

https://doi.org/10.1182/blood-2025-7247

Published: 2025

Journal Articles

Interferon-γ sparks inflammatory fire in Castleman disease

Frits van Rhee, David Fajgenbaum

Blood (2025) 146 (1): 5–7.

https://doi.org/10.1182/blood.2025029270

Published: 2025

Journal Articles

Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes

Nishanth Thalambedu, Jeffery Sawyer, Janet L Lukacs, Phil Farmer, Samer Al-Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Frits van Rhee, Maurizio Zangari

Blood (2024) 144 (Supplement 1): 4726.

https://doi.org/10.1182/blood-2024-211798

Published: 2024

Journal Articles

Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Bhavesh Mohan Lal, Toshali Pandey, Marah Alzubi, Jawad Alrawabdeh, John D Shaughnessy, Jr, Fenghuang Zhan, Eric Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi

Blood (2024) 144 (Supplement 1): 2405.

https://doi.org/10.1182/blood-2024-206497

Published: 2024

Journal Articles

The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans

Yihao Zhan, Hongling Peng, David E. Mery, Eric Siegel, Clyde Bailey, Catherine Ma, Hongwei Xu, Daisy V. Alapat, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 1904.

https://doi.org/10.1182/blood-2024-203848

Published: 2024

Journal Articles

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Asis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, Binod Dhakal, Maurizio Zangari, Samer Al Hadidi, Suzanne Lentzsch, Frits van Rhee, Anita D'Souza, Rajshekhar Chakraborty, Nishi Shah, Mansi R. Shah, Meera Mohan, Carolina Schinke

Blood (2024) 144 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2024-210478

Published: 2024

Journal Articles

Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Sharmilan Thanendrarajan, Phil Farmer, Clyde Bailey, Carolina Schinke, Samer Al Hadidi, Maurizio Zangari, Stephanie Rogers, Anne Williams, Fenghuang Zhan, John D Shaughnessy, Jr, Tanvi H. Patel, Anup Kumar Trikannad, Asis Shrestha, Syed Naqvi, Hira Imad Cheema, Trilok Shrivastava, Manozna Karri, Ramya Bachu, Frits van Rhee

Blood (2024) 144 (Supplement 1): 4713.

https://doi.org/10.1182/blood-2024-206152

Published: 2024

Journal Articles

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Blood (2024) 144 (Supplement 1): 256.

https://doi.org/10.1182/blood-2024-199374

Published: 2024

Journal Articles

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Blood (2024) 144 (Supplement 1): 254.

https://doi.org/10.1182/blood-2024-210725

Published: 2024

Journal Articles

Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression

Visanu Wanchai, Hongwei Xu, Cody Ashby, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 1885.

https://doi.org/10.1182/blood-2024-205344

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab

Comparable response rates to therapies in idiopathic multicentric castleman disease patients with and without expert-confirmed diagnoses

Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor

Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network.

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network.

Siltuximab-mediated suppression of CRP is associated with clinical response in idiopathic multicentric castleman disease

Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum

Transcriptomic and pathological insights into PI3K–Akt pathway activation in idiopathic multicentric castleman disease, tafro and NOS subtypes

Real-world outcomes of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) following CAR T-cell therapy: A multicenter retrospective study from the trinetx global network

Interferon-γ sparks inflammatory fire in Castleman disease

Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes

Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience

The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only